Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Razor Group has successfully closed their €70 Million Series C
EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Razor Group has successfully closed their €70 Million Series C
EQS-News: Heliad Equity Partners GmbH & Co. KGaA: Razor Group has successfully closed their €70 Million Series C
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Unaudited NAV for November 2022
Unaudited NAV for November 2022
Unaudited NAV for November 2022
Arix to Present at Mello Investment Trusts & Funds
Arix to Present at Mello Investment Trusts & Funds
Arix to Present at Mello Investment Trusts & Funds
Unaudited NAV for October 2022
Unaudited NAV for October 2022
Unaudited NAV for October 2022
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
Unaudited NAV for September 2022
Unaudited NAV for September 2022
Unaudited NAV for September 2022
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding
Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
Unaudited NAV for August 2022
Unaudited NAV for August 2022
Unaudited NAV for August 2022
DGAP-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad has signed the UN-supported Principles for Responsible Investments (PRI)
DGAP-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad has signed the UN-supported Principles for Responsible Investments (PRI)
DGAP-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad has signed the UN-supported Principles for Responsible Investments (PRI)
Unaudited NAV for July 2022
Unaudited NAV for July 2022
Unaudited NAV for July 2022
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
Arix Bioscience plc Announces Changes to Board of Directors
Arix Bioscience plc Announces Changes to Board of Directors
Arix Bioscience plc Announces Changes to Board of Directors
Interim Results for the Six Months Ended 30 June 2022
Interim Results for the Six Months Ended 30 June 2022
Interim Results for the Six Months Ended 30 June 2022
Notice of Results & Investor Presentation
Notice of Results & Investor Presentation
Notice of Results & Investor Presentation
Unaudited NAV for June 2022
Unaudited NAV for June 2022
Unaudited NAV for June 2022
Edison Investment Research Limited: Heliad Equity Partners (HEP): Initiation - A high-tech growth investor from Germany
Edison Investment Research Limited: Heliad Equity Partners (HEP): Initiation - A high-tech growth investor from Germany
Edison Investment Research Limited: Heliad Equity Partners (HEP): Initiation - A high-tech growth investor from Germany
Tetragon Financial Group (TFG): Offering a diverse exposure to alternative assets
Tetragon Financial Group (TFG): Offering a diverse exposure to alternative assets
Tetragon Financial Group (TFG): Offering a diverse exposure to alternative assets
DGAP-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad invests in the Series B  funding of HR-Tech company WorkMotion
DGAP-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad invests in the Series B funding of HR-Tech company WorkMotion
DGAP-News: Heliad Equity Partners GmbH & Co. KGaA: Heliad invests in the Series B funding of HR-Tech company WorkMotion
Notice of Investor Presentation
Notice of Investor Presentation
Notice of Investor Presentation
Unaudited NAV for May 2022
Unaudited NAV for May 2022
Unaudited NAV for May 2022
Result of Annual General Meeting 2022
Result of Annual General Meeting 2022
Result of Annual General Meeting 2022